Antihemorrhagic

2022 Military Medical Device Technologies Report - Easy-to-Use and Quick Wound Sealing Hemostatic Solutions for Trauma Injuries Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Medical Devices, Health, Digital, Adoption, Military personnel, Antihemorrhagic, Sexual Assault Prevention Response (US military), Partnering, Troop, Soldier, Health technology, Risk, Use, Technology, Solution, Care, Development, Computer security, Commonly used gamma-emitting isotopes, Vels Institute of Science, Technology & Advanced Studies, Macedonian Federative Organization, Partnership, Medtech, Emerging technologies, Military, Bandage, Injury, Mental health, Key, Connectivity, Pharmaceutical industry, Medicine, Weapon, Risk management, Satellite navigation device, Defense, Hemostasis

The Key Innovation Areas in Military Health Systems Include Wound Care, Health Monitoring, and Human Augmentation.

Key Points: 
  • The Key Innovation Areas in Military Health Systems Include Wound Care, Health Monitoring, and Human Augmentation.
  • US and Chinese Defense Bodies are Adopting Emerging Technologies in Military Health, Especially Digital Technologies.
  • Smart Garments and Robotic Exoskeletons are the Most Impactful Emerging Medical Technologies in Military Health Systems.
  • Hemostatic and Health Monitoring are Easy-to-Implement and Highly Impactful Solutions that Improve the Health of Military Personnel.

Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio

Retrieved on: 
Thursday, July 29, 2021
Medical devices, Health, Hospitals, Surgery, Clinical trials, Pharmaceutical, Medicine, Health sciences, Health care, Medical terminology, Antihemorrhagic, Shaving, Transfusion medicine, Hematology, Adhesion barrier, Hemostasis, Topical medication, Hemostat

PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.

Key Points: 
  • PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.
  • The trial evaluated the safety and efficacy of PerClot in achieving intraoperative hemostasis compared to the control (a similar marketed hemostatic powder).
  • Combined use of PerClot PHS with other topical hemostatic agents has not been studied in controlled clinical trials.
  • This release includes forward-looking statements concerning a definitive agreement entered into by Baxter to acquire PerClot Polysaccharide Hemostatic System from CryoLife, including expectations regarding the financial impact and other benefits of such acquisition for Baxter.

Medcura Launches a New Class of High-Performance, Antibacterial Hemostats

Retrieved on: 
Monday, July 12, 2021
Antihemorrhagic, Shaving, Transfusion medicine

By combining more exact delivery and highly effective wound sealing, Medcura's gel provides the consumer with greater per use value.

Key Points: 
  • By combining more exact delivery and highly effective wound sealing, Medcura's gel provides the consumer with greater per use value.
  • Working with the marketing team at ASO, Medcura developed both travel (0.3 oz) and family size (0.5 oz) formats to readily fulfill customer needs.
  • "We've partnered with Medcura to bring affordable state of the art first aid products to the OTC retail marketplace."
  • Medcura is a commercial-stage medical device company developing versatile hemostatic products for surgical, medical, and consumer applications.

Tricol Biomedical launches sales and marketing agency agreement with NorthStar Sales Alliance

Retrieved on: 
Wednesday, May 5, 2021
Medical specialties, Antihemorrhagic, Shaving, Transfusion medicine, Northstar, Major trauma, Clinical medicine, Medicine

b'Portland, OR, May 05, 2021 (GLOBE NEWSWIRE) -- Tricol Biomedical, a privately held medical device company dedicated to saving lives through innovative hemostatic and wound care solutions, today announced a unique sales and marketing agency agreement for the Tricol Biomedical family of hemostatic products with NorthStar Sales Alliance.

Key Points: 
  • b'Portland, OR, May 05, 2021 (GLOBE NEWSWIRE) -- Tricol Biomedical, a privately held medical device company dedicated to saving lives through innovative hemostatic and wound care solutions, today announced a unique sales and marketing agency agreement for the Tricol Biomedical family of hemostatic products with NorthStar Sales Alliance.
  • NorthStar is a healthcare company with broad access into both the acute care and alternate site markets in US.
  • Tricol products are successfully used to meet a variety of medical needs\xe2\x80\x94from Trauma Management to Procedural Care to Consumer Care\xe2\x80\x94and the Tricol product portfolio now features over-the-counter advanced wound care products as well.\n\xe2\x80\x9cThis sales and marketing agreement with NorthStar is consistent with our mission to provide access to Tricol Biomedical products across the full spectrum of the healthcare market.
  • Tricol Biomedical is fully committed to innovation in bleeding control and wound care technology.

GATT announces first-in-man use of 'GATT-Patch', a hemostatic sealant patch, by Radboud university medical center Nijmegen

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Transfusion medicine, Clinical medicine, Medicine, Antihemorrhagic, Shaving, Hemostat, Radboud University Nijmegen, Radboud University Medical Center, Bleeding, Hepatectomy, Radbod

b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).

Key Points: 
  • b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).
  • Having fast and effective solutions to manage complex bleeding is crucial to prevent complications for patients during or after surgery.
  • Hemostats and sealants are used when other methods to contain the bleeding are ineffective or insufficient.
  • Stuart Head, Chief Medical Officer of GATT, commented: "Principal investigators Professor dr. de Wilt (Radboudumc), Professor dr. Porte (University Medical Center Groningen), and Professor dr. Verhoef (Erasmus Medical Center) and their teams are a fantastic group to work with.

GATT announces first-in-man use of 'GATT-Patch', a hemostatic sealant patch, by Radboud university medical center Nijmegen

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Transfusion medicine, Clinical medicine, Medicine, Antihemorrhagic, Shaving, Hemostat, Radboud University Nijmegen, Radboud University Medical Center, Bleeding, Hepatectomy, Radbod

b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).

Key Points: 
  • b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).
  • Having fast and effective solutions to manage complex bleeding is crucial to prevent complications for patients during or after surgery.
  • Hemostats and sealants are used when other methods to contain the bleeding are ineffective or insufficient.
  • Stuart Head, Chief Medical Officer of GATT, commented: "Principal investigators Professor dr. de Wilt (Radboudumc), Professor dr. Porte (University Medical Center Groningen), and Professor dr. Verhoef (Erasmus Medical Center) and their teams are a fantastic group to work with.

Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology

Retrieved on: 
Monday, April 19, 2021
Branches of biology, Biology, Blood, Hematology, Gene therapy, Antihemorrhagic, Haemophilia

b'SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the publication of preclinical data from its study of CB 2679d-GT in Hemophilia B mice in Blood, the peer-reviewed, official journal of the American Society of Hematology.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the publication of preclinical data from its study of CB 2679d-GT in Hemophilia B mice in Blood, the peer-reviewed, official journal of the American Society of Hematology.
  • A significantly reduced bleeding time and total blood loss with CB 2679d-GT gene therapy compared to mice treated with R338L-Padua demonstrated a more rapid and robust hemostatic correction.
  • Thus, CB 2679d-GT could potentially allow for lower and safer vector doses in future human trials.\n"The data demonstrate the strong potential of our gene therapy candidate," said\xc2\xa0Grant Blouse, Ph.D., Senior Vice President, Translational Research at Catalyst Biosciences.
  • The Company does not assume any obligation to update any forward-looking statements, except as required by law.\n'

Cellphire Therapeutics Names Michael Gaffney as Company's New CEO

Retrieved on: 
Tuesday, April 20, 2021
Gaffney, Antihemorrhagic

b'ROCKVILLE, Md., April 20, 2021 /PRNewswire/ --Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately.

Key Points: 
  • b'ROCKVILLE, Md., April 20, 2021 /PRNewswire/ --Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately.
  • Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire.
  • He will also join the Company\'s board.\n"We\'re thrilled to have Mike join the Cellphire team," said Tom Dubin, Executive Chairman.
  • I believe the work we are doing in platelet-based therapeutics has the potential to revolutionize how bleeding patients are treated, with a broad range of additional indications relevant to the company\'s scientific portfolio," said Michael Gaffney, CEO.

Tricol Biomedical co-develops cutting-edge convenience kit with Tactical Medical Solutions

Retrieved on: 
Tuesday, April 6, 2021
Medical dressings, Medicine, Clinical medicine, Antihemorrhagic, Dressing, Bandage, Wound, Branches of biology

Portland, OR, April 06, 2021 (GLOBE NEWSWIRE) -- Tricol Biomedical and Tactical Medical Solutions have partnered to launch the next generation of the OLAES Modular Bandage.

Key Points: 
  • Portland, OR, April 06, 2021 (GLOBE NEWSWIRE) -- Tricol Biomedical and Tactical Medical Solutions have partnered to launch the next generation of the OLAES Modular Bandage.
  • Having used trauma dressings in the field personally, I know how impactful this convenience kit is going to be to this industry.
  • Tricol Biomedical is a fully integrated medical device company that is dedicated to significantly advancing the standard of care in hemostatic and wound care solutions with the HemCon brand of products.
  • Tactical Medical Solutions is a global leading developer and manufacturer of pre-hospital medical gear for the tactical and civilian world.

FDA Approves EndoClot® Hemostat to Manage GI Bleeding

Retrieved on: 
Tuesday, February 23, 2021
Biotechnology, FDA, Surgery, Medical devices, Health, Antihemorrhagic, Shaving, Transfusion medicine, Starch, Hemostat, Health, Branches of biology, Medical specialties

EndoClot Plus, Inc. (EPI) announced the U.S. Food and Drug Administration (FDA) has approved EndoClot Polysaccharide Hemostatic System (EndoClot PHS), an innovative product that assists Gastroenterologists to stop bleeding rapidly and reliably.

Key Points: 
  • EndoClot Plus, Inc. (EPI) announced the U.S. Food and Drug Administration (FDA) has approved EndoClot Polysaccharide Hemostatic System (EndoClot PHS), an innovative product that assists Gastroenterologists to stop bleeding rapidly and reliably.
  • EndoClot PHS is a single use device including a starch-based powder hemostat that is applied directly to the bleeding site through a flexible endoscope.
  • The FDA clearance of EndoClot PHS represents a significant milestone in advancing the care of the GI patient.
  • EndoClot Plus Co., Ltd. located in Suzhou, China is the manufacturer of the EndoClot product lines including EndoClot PHS, EndoClot Adhesive and EndoClot Submucosal Injection System.